AMP

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	11

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

trials per page:

Showing 1 to 10 of 11 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04068246 (ClinicalTrials.gov)	August 1, 2019	21/8/2019	The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Pati ...	The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Pati ...	Rheumatoid Arthritis	Drug: Metformin;Drug: Placebo	Sadat City University	NULL	Completed	18 Years	N/A	All	120	Phase 1/Phase 2	Egypt
2	NCT02277574 (ClinicalTrials.gov)	June 2014	23/7/2014	Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheu ...	A Randomized, Multi-Dose, Placebo-Controlled, Study of the Safety, Tolerability, Pharmacokinetics an ...	Rheumatoid Arthritis	Biological: AMP-110;Other: Placebo	MedImmune LLC	Daiichi Sankyo Co., Ltd.	Completed	18 Years	75 Years	Both	29	Phase 1	United States
3	NCT01851278 (ClinicalTrials.gov)	April 2013	12/4/2013	Effectiveness Intraarticular Corticosteroid	Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose	Rheumatoid Arthritis	Drug: Triamcinolone hexacetonide	Federal University of São Paulo	Fundação de Amparo à Pesquisa do Estado de São Paulo	Recruiting	18 Years	65 Years	Both	60	N/A	Brazil
4	NCT01878123 (ClinicalTrials.gov)	April 2013	22/5/2013	Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoi ...	A Randomized, Single-Dose, Placebo-Controlled, Study of the Safety, Tolerability, and Pharmacokineti ...	Rheumatoid Arthritis	Biological: AMP-110;Other: Placebo	MedImmune LLC	Daiichi Sankyo Co., Ltd.;Daiichi Sankyo Co., Ltd.	Completed	18 Years	75 Years	Both	26	Phase 1	United States
5	JPRN-UMIN000008812	2012/10/01	01/10/2012	Efficacy and safety of tocilizumab mono-therapy in patients with large vessel vasculitis (LVV; giant ...	Efficacy and safety of tocilizumab mono-therapy in patients with large vessel vasculitis (LVV; giant ...	Rheumatoid arthritis	tocilizumab monotherapy	Department of Rheumatology & Clinical ImmunologySaitama Medical Center, Saitama Medical Universi ...	NULL	Complete: follow-up complete	16years-old	80years-old	Male and Female	40	Not selected	Japan
6	JPRN-UMIN000007019	2012/02/01	01/02/2012	Efficacy and safety of tocilizumab mono-therapy in patients with adult-onset Still's disease	Efficacy and safety of tocilizumab mono-therapy in patients with adult-onset Still's disease - Treat ...	Rheumatoid arthritis	tocilizumab monotherapy	Department of Rheumatology & Clinical Immunology,Saitama Medical Center, Saitama Medical Univers ...	NULL	Complete: follow-up complete	16years-old	70years-old	Male and Female	40	Not selected	Japan
7	JPRN-UMIN000005773	2011/06/01	14/06/2011	Magnetic resonance image analysis for quantification of knee articular cartilage verified response t ...	Magnetic resonance image analysis for quantification of knee articular cartilage verified response t ...	rheumatoid arthritis	ETN+MTX MTX	22nd Century Medical & Research Center, the University of Tokyo	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	20	Not selected	Japan
8	NCT01151644 (ClinicalTrials.gov)	April 2010	25/6/2010	Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases	Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases	Rheumatoid Arthritis;Spondyloarthritis;Systemic Lupus Erythematosus (SLE);Dermatomyositis (DM);DMixe ...	Biological: Anti-pandemic H1N1 influenza vaccine	University of Sao Paulo	Fundação de Amparo à Pesquisa do Estado de São Paulo	Active, not recruiting	N/A	N/A	Both	5000	Phase 4	Brazil
9	JPRN-UMIN000001240	2008/07/01	10/07/2008	The efficacy of tocilizumab to patients with rheumatoid arthritis refractory to anti-TNF agents: the ...	The efficacy of tocilizumab to patients with rheumatoid arthritis refractory to anti-TNF agents: the ...	rheumatoid arthritis	Tocilizumab (8 mg/kg of body weight) is to be infused every 4 weeks for 3 years	Division of Rheumatology & Clinical Immunology, Jichi Medical University	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	20	Not selected	Japan
10	NCT00239382 (ClinicalTrials.gov)	July 1, 2004	13/10/2005	A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheum ...	A Randomized, Open-labelled Study to Compare the Efficacy and Safety of Meloxicam 15 mg IM Ampoules ...	Arthritis, Rheumatoid	Drug: Meloxicam ampoule;Drug: Meloxicam tablet	Boehringer Ingelheim	NULL	Completed	18 Years	N/A	All	150	Phase 3	China

First Previous1 2Next Last